Evidence map›Paper›PMID 42362801›Full record

ArticleEuropean journal of human genetics : EJHG2026

Decoding splicing variants in high-throughput sequencing: a functional validation approach integrating deep learning tools.

Clément Hersent, Lise Larrieu, Patricia Fergelot, Julie Miro, Mehdi Benkirane, Chloé Angelini, Francis Ramond, Cecilia Marelli, Isabelle Sabatier, Gaëtan Lesca and 12 more

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Beyond the sequence.European journal of human genetics : EJHG · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Clément HersentLaboratoire de Génétique Moléculaire de Maladies Rares, Site Unique de Biologie, CHU de Montpellier, Montpellier, France. clement.hersent@inserm.fr.ORCID http://orcid.org/0009-0000-6505-3814
Lise LarrieuLaboratoire de Génétique Moléculaire de Maladies Rares, Site Unique de Biologie, CHU de Montpellier, Montpellier, France.
Patricia FergelotNeurogenetics Reference Centre, Department of Medical Genetics, Bordeaux University Hospital, Bordeaux, France.
Julie MiroPhyMedExp, Univ Montpellier, CNRS, INSERM, Montpellier, France.ORCID http://orcid.org/0000-0003-0913-6126
Mehdi BenkiraneLaboratoire de Génétique Moléculaire de Maladies Rares, Site Unique de Biologie, CHU de Montpellier, Montpellier, France.
Chloé AngeliniNeurogenetics Reference Centre, Department of Medical Genetics, Bordeaux University Hospital, Bordeaux, France.
Francis RamondDepartment of Medical Genetics, CHU of Saint-Etienne, Saint-Etienne, France.ORCID http://orcid.org/0000-0003-4540-8096
Cecilia MarelliMMDN, Université de Montpellier, EPHE, INSERM, Montpellier, France.
Isabelle SabatierDepartment of Pediatric Neurology, University Hospitals of Lyon, Lyon, France.
Gaëtan LescaDepartment of Medical Genetics, University Hospitals of Lyon and Université Claude Bernard Lyon1, Lyon, France.ORCID http://orcid.org/0000-0001-7691-9492
Christel VachéLaboratoire de Génétique Moléculaire de Maladies Rares, Site Unique de Biologie, CHU de Montpellier, Montpellier, France.ORCID http://orcid.org/0000-0001-7076-9139
Mireille CosséeLaboratoire de Génétique Moléculaire de Maladies Rares, Site Unique de Biologie, CHU de Montpellier, Montpellier, France.ORCID http://orcid.org/0000-0002-5931-7454
Anne BergougnouxLaboratoire de Génétique Moléculaire de Maladies Rares, Site Unique de Biologie, CHU de Montpellier, Montpellier, France.
Klaus DieterichDepartment of Medical Genetics, CHU de Grenoble, Grenoble, Université Grenoble Alpes, INSERM U 1209, CNRS UMR 5309, Institut for Advanced Biosciences, Grenoble, France.ORCID http://orcid.org/0000-0002-4362-4062
Christine TranchantDepartment of Neurology, Hôpitaux Universitaires de Strasbourg, Strasbourg; Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.
Isabelle MareyDepartment of Medical Genetics, CHU de Grenoble, Grenoble, Université Grenoble Alpes, INSERM U 1209, CNRS UMR 5309, Institut for Advanced Biosciences, Grenoble, France.
Anna CastriotoGrenoble Institute of Neurosciences, Grenoble Alpes University Hospital Center, Inserm, U1216, Grenoble Alpes University, Grenoble, France.
Christel Thauvin-RobinetUniversité de Bourgogne Europe, CHU Dijon Bourgogne, Centre de Génétique, Centre de Référence Maladies Rares Neurogène, INSERM, CTM UMR 1231, GAD, Dijon, France.ORCID http://orcid.org/0000-0002-4155-139X
Lydia Abou HaidarDepartment of Pediatric Neurology and Reference Center for Neuromuscular Diseases AOC, Gui de Chauliac Hospital, CHU de Montpellier, Montpellier, France.
François RivierPhyMedExp, Univ Montpellier, CNRS, INSERM, Montpellier, France.
Sylvie Tuffery-GiraudPhyMedExp, Univ Montpellier, CNRS, INSERM, Montpellier, France.
Michel KoenigLaboratoire de Génétique Moléculaire de Maladies Rares, Site Unique de Biologie, CHU de Montpellier, Montpellier, France. michel.koenig@inserm.fr.ORCID http://orcid.org/0009-0007-2421-212X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-throughput genome and exome sequencing have uncovered numerous intronic variants in disease genes, yet predicting their impact on pre-mRNA splicing is still challenging. While deep learning tools have improved variant prioritization, their ability to detect atypical regulatory mechanisms remains unknown. We combined predictions from multiple complementary splicing prediction tools with functional RNA studies to evaluate the splicing consequences of intronic variants identified in patients with neurodegenerative diseases. Nine intronic variants with uncertain impact on splicing were selected, including six deep-intronic variants, two non-canonical splice-site variants, and one canonical splice-site variant associated with an atypical phenotype. Three variants were predicted to disrupt a donor splice site, five to create a cryptic donor splice site, and one was located close to a putative acceptor site. Transcript analysis in blood revealed splicing abnormalities in eight of the nine cases. All algorithms failed at least once: deep learning tools missed specific donor site losses or cryptic splice-site activation events, while motif-based approaches failed to predict some donor site activation or generated false-positive predictions. The only variant not directly located in a splice site was predicted to activate a deep intronic splicing enhancer. Motif-based tools suggested the creation of an SRSF2 protein-dependent enhancer. Functional studies based on minigene assays support a role for SRSF2 in promoting pseudoexon inclusion. These findings highlight the complementarity of splicing prediction tools and the need to integrate them into diagnostic pipelines, with transcript-level confirmation remaining critical for accurate pathogenicity assessment.

Indexed as

Deep LearningHigh-Throughput Nucleotide SequencingNeurodegenerative DiseasesRNA SplicingHumansIntronsRNA Splice SitesRNA Splice Sites

Identifiers

PMID42362801
PMCPMC13424874

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.